TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$94 Million

Editas Medicine

Initial Public Offering

Lead Manager, February 2016

Editas Medicine
Editas is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The Company is developing a proprietary genome editing platform based on CRISPR technology. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 or Cpf1, bound to a guide RNA molecule designed to recognize a particular DNA sequence. Once the complex binds to the DNA sequence it was designed to recognize, the complex makes a specific cut in the DNA, ultimately triggering the cell’s DNA repair machinery to change the targeted sequence. The platform consists of four interrelated components: nuclease engineering, delivery, control and specificity, and directed editing. These components are designed to develop medicines that specifically address a wide variety of genetic targets, reach the site of disease safely and effectively, tightly and specifically control the editing process, and drive the right kind of genetic repair. The Company’s preclinical drug discovery platform uses the flexibility of CRISPR technology to enable rapid reprogramming of the guide RNA complex with the potential to direct it to almost any site in the human genome. Using this platform, Editas aims to develop and advance a broad range of therapies for genetically defined diseases.